BYSI.O (BYSI.O) News
Follow BYSI.O (BYSI.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
BeyondSpring says FDA Fast Track for plinabulin with docetaxel in NSCLC Phase 3
BeyondSpring said the FDA granted Fast Track status for plinabulin with docetaxel in later-line advanced non-squamous NSCLC without actionable genomic alterations. The designation supports its global Phase 3 DUBLIN-4 stu
EARNINGS | Sep 29, 2026, 11:20 AM UTC
M
BeyondSpring sells majority stake in China unit Bulin to Biolin to fund DUBLIN-4 trial
BeyondSpring will sell its China unit Bulin, which it indirectly owns a majority stake in, to Biolin Investment in non-cash consideration funding DUBLIN-4 development in China covering about 221 patients.
MNA | Sep 29, 2026, 11:10 AM UTC
L
BeyondSpring risks Nasdaq delisting after shares trade below $1 for 30 days
BeyondSpring received a Nasdaq notice on Sept. 17, 2026 for failing the $1 minimum bid price rule. Ordinary shares traded below $1 for 30 consecutive business days, breaching Nasdaq Listing Rule 5550(a)(2). Nasdaq grante
REGULATION | Sep 18, 2026, 08:32 PM UTC